INCREMENTAL REIMBURSEMENT GRANTED IN FRANCE FOR THE CYPHER SIROLIMUS-ELUTING CORONARY STENT AND CYPHER SELECT SIROLIMUS-ELUTING CORONARY STENT

The excellent efficacy and safety data for the CYPHER Stent is prompting a significant change in French reimbursement for this medical device, which has been quickly adopted by cardiologists in the treatment of patients with coronary blockages. The CYPHER Stent and its next generation stent, CYPHER SELECT, are now the only drug-eluting stents in France to have reimbursement for in-stent restenosis for diabetic and non diabetic patients, and for treatment of multiple lesions per procedure (one stent per artery, three stents maximum per patient) for both non-diabetic, as well as diabetic patients.

PR Newswire (http://www.prnewswire.co.uk/cgi/news/release?id=160443)